Nuvectis Pharma, Inc.

NasdaqCM NVCT

Nuvectis Pharma, Inc. Market Capitalization on January 14, 2025: USD 108.97 M

Nuvectis Pharma, Inc. Market Capitalization is USD 108.97 M on January 14, 2025, a -20.69% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Nuvectis Pharma, Inc. 52-week high Market Capitalization is USD 212.14 M on November 12, 2024, which is 94.68% above the current Market Capitalization.
Nuvectis Pharma, Inc. 52-week low Market Capitalization is USD 87.33 M on December 20, 2024, which is -19.86% below the current Market Capitalization.
Nuvectis Pharma, Inc. average Market Capitalization for the last 52 weeks is USD 129.80 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: NVCT

Nuvectis Pharma, Inc.

CEO	Mr. Ron Bentsur M.B.A.
IPO Date	Feb. 4, 2022
Location	United States
Headquarters	1 Bridge Plaza
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Key trends

Past 5 years